-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, while listed companies have disclosed their 2021 annual reports, their performance in the first quarter of 2022 has also been gradually announc.
In terms of net profit, there are 15 pharmaceutical companies with a net profit of over 1 billion yuan in the first quarter, among which Jiu'an Medical ranks first with a net profit of 13 billion yuan, while Changchun High-tech, Zhifei Bio, Wantai Bio, and Mingde The five pharmaceutical companies, Biotech and Aotai Biotech, entered the "1 billion club" for the first ti.
According to the first quarterly report of Jiu'an Medical in 2022, the company achieved revenue of 274 billion yuan, a year-on-year increase of 6648%; net profit was 131 billion yuan, a year-on-year increase of 3752
In 2021, the company also achieved good results of double growth in revenue and net prof.
Regarding the reasons for the substantial increase in performance, the company stated at the online performance briefing for 2021 and the first quarter of 2022 that the company's performance in the first quarter of 2022 increased significantly compared with the same period last year, mainly due to the increase in the sales revenue of iHealth kit produc.
However, it is currently impossible to accurately predict the future sales of the company's iHealth ki.
Public information shows that Jiu'an Medical is a listed company focusing on the R&D and production of health electronic products and intelligent hardware, and an innovative personal health management cloud platform focusing on building a mobile Internet "smart hardware + mobile application + cloud servic.
technology compani.
The company was listed on the Shenzhen SME Board on June 10, 201 In the first quarter of 2022, Changchun Hi-Tech recorded revenue of about 975 billion yuan, a year-on-year increase of 34%; net profit of about 138 billion yuan, a year-on-year increase of 316%; basic earnings per share of 83 yuan, a year-on-year increase of 30
For the increase in revenue, the company said that the main reason was the increase in sales revenue of Kinsey Pharmaceutica.
In the first quarter, Jinsai Pharmaceutical achieved revenue of 648 billion yuan, a year-on-year increase of 469%; net profit of 205 billion yuan, a year-on-year increase of 33
According to the data, Jinsai Pharmaceutical is a large-scale recombinant human growth hormone manufacturer in Asia, and it is also a company with a matrix of growth hormone powder injections, water injections, and long-acting dosage forms in Chi.
On March 10, 2022, the results of the centralized procurement were announc.
The powder injection was to be selected by Jinsai Pharmaceuticals and United Purcell, but there was no valid declaration for the water injecti.
This means that the price system in the water injection field, which accounts for more than 70% of Jinsai Pharmaceutical's revenue, remains stable, and the company's growth hormone business is basically unaffect.
In this regard, some analysts pointed out that the three powder injection specifications tendered by Jinsai Pharmaceuticals were 546% lower than the maximum effective price limit, which is expected to establish a larger market share in the futu.
In addition, long-acting growth hormone, as the company's exclusive variety, is expected to achieve rapid growth with the intensification of promotion, and its proportion will continue to increa.
In the first quarter of 2022, Zhifei Bio achieved total operating income of 841 billion yuan, a year-on-year increase of 1216%; net profit attributable to the parent was 923 billion yuan, a year-on-year increase of 109
Previously, the company stated in its performance pre-increase announcement that the main reason for the change in performance was that the company steadily promoted product research and development, production, promotion, sales and other work around the annual business goals and pla.
According to the data, Zhifei Bio’s main business includes vaccine and biological product research and development, production and sal.
The company mentioned in its reply to investors at the end of April, "In the first quarter, the number of HPV vaccines issued in batches increased significantly compared with the same period of the previous ye.
The quadrivalent HPV vaccine was issued in batches of 11 million, an increase of nearly 70%; the nine-valent HPV vaccine was issued in batch.
83 million, an increase of nearly 28
" In addition, Wantai Bio, Mingde Bio, and Aotai Bio achieved net profits of 331 billion yuan, 389 billion yuan, and 049 billion yuan respectively in the first quarter of 2022; a year-on-year increase of 3618% respectively , 3005%, 591
Click to enter the exhibition page
In terms of net profit, there are 15 pharmaceutical companies with a net profit of over 1 billion yuan in the first quarter, among which Jiu'an Medical ranks first with a net profit of 13 billion yuan, while Changchun High-tech, Zhifei Bio, Wantai Bio, and Mingde The five pharmaceutical companies, Biotech and Aotai Biotech, entered the "1 billion club" for the first ti.
According to the first quarterly report of Jiu'an Medical in 2022, the company achieved revenue of 274 billion yuan, a year-on-year increase of 6648%; net profit was 131 billion yuan, a year-on-year increase of 3752
In 2021, the company also achieved good results of double growth in revenue and net prof.
Regarding the reasons for the substantial increase in performance, the company stated at the online performance briefing for 2021 and the first quarter of 2022 that the company's performance in the first quarter of 2022 increased significantly compared with the same period last year, mainly due to the increase in the sales revenue of iHealth kit produc.
However, it is currently impossible to accurately predict the future sales of the company's iHealth ki.
Public information shows that Jiu'an Medical is a listed company focusing on the R&D and production of health electronic products and intelligent hardware, and an innovative personal health management cloud platform focusing on building a mobile Internet "smart hardware + mobile application + cloud servic.
technology compani.
The company was listed on the Shenzhen SME Board on June 10, 201 In the first quarter of 2022, Changchun Hi-Tech recorded revenue of about 975 billion yuan, a year-on-year increase of 34%; net profit of about 138 billion yuan, a year-on-year increase of 316%; basic earnings per share of 83 yuan, a year-on-year increase of 30
For the increase in revenue, the company said that the main reason was the increase in sales revenue of Kinsey Pharmaceutica.
In the first quarter, Jinsai Pharmaceutical achieved revenue of 648 billion yuan, a year-on-year increase of 469%; net profit of 205 billion yuan, a year-on-year increase of 33
According to the data, Jinsai Pharmaceutical is a large-scale recombinant human growth hormone manufacturer in Asia, and it is also a company with a matrix of growth hormone powder injections, water injections, and long-acting dosage forms in Chi.
On March 10, 2022, the results of the centralized procurement were announc.
The powder injection was to be selected by Jinsai Pharmaceuticals and United Purcell, but there was no valid declaration for the water injecti.
This means that the price system in the water injection field, which accounts for more than 70% of Jinsai Pharmaceutical's revenue, remains stable, and the company's growth hormone business is basically unaffect.
In this regard, some analysts pointed out that the three powder injection specifications tendered by Jinsai Pharmaceuticals were 546% lower than the maximum effective price limit, which is expected to establish a larger market share in the futu.
In addition, long-acting growth hormone, as the company's exclusive variety, is expected to achieve rapid growth with the intensification of promotion, and its proportion will continue to increa.
In the first quarter of 2022, Zhifei Bio achieved total operating income of 841 billion yuan, a year-on-year increase of 1216%; net profit attributable to the parent was 923 billion yuan, a year-on-year increase of 109
Previously, the company stated in its performance pre-increase announcement that the main reason for the change in performance was that the company steadily promoted product research and development, production, promotion, sales and other work around the annual business goals and pla.
According to the data, Zhifei Bio’s main business includes vaccine and biological product research and development, production and sal.
The company mentioned in its reply to investors at the end of April, "In the first quarter, the number of HPV vaccines issued in batches increased significantly compared with the same period of the previous ye.
The quadrivalent HPV vaccine was issued in batches of 11 million, an increase of nearly 70%; the nine-valent HPV vaccine was issued in batch.
83 million, an increase of nearly 28
" In addition, Wantai Bio, Mingde Bio, and Aotai Bio achieved net profits of 331 billion yuan, 389 billion yuan, and 049 billion yuan respectively in the first quarter of 2022; a year-on-year increase of 3618% respectively , 3005%, 591
Click to enter the exhibition page
